Nicolet Advisory Services, LLC Genprex, Inc. Transaction History

Nicolet Advisory Services, LLC

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2022 Feb 09, 2023	SELL	$1.0 - $58.8 $5,000 - $294,000	-5,000 Reduced 33.33%	10,000 $14,000
Q3 2020 Oct 27, 2020	BUY	$2.9 - $4.29 $43,500 - $64,350	15,000 New	15,000 $50,000

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $112M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Nicolet Advisory Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Nicolet Advisory Services, LLC with notifications on news.